{"entity":{"id":"nct06264180","kind":"trial","name":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","aka":[],"tldr":"A phase 3 trial of Vusolimogene oderparepvec, Nivolumab, Relatlimab + nivolumab and Pembrolizumab in Advanced melanoma, run by Replimune, Inc., now recruiting.","summary":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] is a phase 3 interventional study registered as NCT06264180 by Replimune, Inc., with 400 participants planned, started 2024-07-11 and due to reach its primary completion in 2030-09-30. Interventions recorded: Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy. Conditions recorded: Advanced Melanoma.\n\nLinked to the drug Vusolimogene oderparepvec because the registry names it among its interventions and Advanced melanoma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06264180","url":"https://clinicaltrials.gov/study/NCT06264180"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["advanced-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["vusolimogene-oderparepvec","nivolumab","relatlimab-nivolumab","pembrolizumab"],"companies":["replimune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06264180","phase":"3","setting":"Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]","sponsor":"Replimune, Inc.","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06264180/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/"},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/"}],"company":[{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/"}]}}